ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 100 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2016. The put-call ratio across all filers is 0.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $92,000 | -10.7% | 7,387 | -0.4% | 0.00% | – |
| Q3 2016 | $103,000 | +60.9% | 7,419 | +14.7% | 0.00% | – |
| Q2 2016 | $64,000 | -37.3% | 6,468 | +7.6% | 0.00% | – |
| Q1 2016 | $102,000 | -23.9% | 6,009 | 0.0% | 0.00% | – |
| Q4 2015 | $134,000 | -33.7% | 6,009 | -29.7% | 0.00% | – |
| Q3 2015 | $202,000 | -78.9% | 8,546 | -27.0% | 0.00% | -100.0% |
| Q2 2015 | $957,000 | +124.6% | 11,704 | +154.3% | 0.00% | – |
| Q1 2015 | $426,000 | +225.2% | 4,602 | +42.2% | 0.00% | – |
| Q4 2014 | $131,000 | +101.5% | 3,236 | +22.7% | 0.00% | – |
| Q3 2014 | $65,000 | +27.5% | 2,638 | -18.6% | 0.00% | – |
| Q2 2014 | $51,000 | -17.7% | 3,239 | -20.8% | 0.00% | – |
| Q1 2014 | $62,000 | -11.4% | 4,092 | -19.4% | 0.00% | – |
| Q4 2013 | $70,000 | -96.9% | 5,079 | -95.7% | 0.00% | -100.0% |
| Q3 2013 | $2,240,000 | – | 118,746 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,679,835 | $69,675,000 | 19.39% |
| Endurant Capital Management LP | 207,293 | $5,390,000 | 1.94% |
| Bellevue Group AG | 5,138,451 | $133,599,000 | 1.53% |
| Rhenman & Partners Asset Management AB | 592,225 | $15,398,000 | 1.26% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,562,869 | $40,635,000 | 0.93% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 31,434 | $817,000 | 0.62% |
| WASATCH ADVISORS LP | 3,998,010 | $103,949,000 | 0.51% |
| HAMILTON LANE ADVISORS LLC | 46,181 | $1,201,000 | 0.45% |
| Boxer Capital, LLC | 500,000 | $13,000,000 | 0.42% |
| DCF Advisers, LLC | 38,500 | $1,001,000 | 0.41% |